• Esra İşçi Bostancı, Yasin Durmuş, A. Sinem Duru Çöteli, Fulya Kayıkçıoğlu, and Nurettin Boran.
• The Department of Gynecologic Oncology, Faculty of Medicine, Gazi University, Ankara, Turkey
• Turk J Med Sci. 2021 Aug 30; 51 (4): 2066-2072.

Background/AimThe objective of the study was to evaluate the response, relapse, reproductive results and demographic features of the patients with endometrioid adenocancer (EAC) and endometrial intraepithelial neoplasia (EIN) who were treated with conservative treatment. This is the largest study when we consider the single center studies in this field.Materials And MethodsIn the current retrospective study, 38 patients (6 EAC, 31 EIN, 1 synchronous tumors of ovary and endometrium) were recruited. They were treated with progesterone products for their fertility desire and comorbidity. Reproductive results, response rates, and recurrence rates were calculated and survival analyses were performed.ResultsMean duration of the medical treatment was 10 months (range 2–60). Among the 32 patients with EIN, 28 (87.5%) had a response, 8 (25%) had a relapse and 4 (12.5%) had persistence. Among the 32 patients who expecting fertility, seven patients got pregnant (21.8%) with a total of five live births. The median follow-up was 40.5 months (range 3–180), and recurrence-free interval was 28.7 months (range 2–180).ConclusionFertility-sparing treatment of EAC and EIN is a feasible approach, and the eligible patients should be given a chance to get pregnant.This work is licensed under a Creative Commons Attribution 4.0 International License.

30 keywords...

hide…